Cargando…
Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
The dynamic interplay between virus and host plays out across many interacting surfaces as virus and host evolve continually in response to one another. In particular, epitope-paratope interactions (EPIs) between viral antigen and host antibodies drive much of this evolutionary race. In this review,...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247215/ https://www.ncbi.nlm.nih.gov/pubmed/35784339 http://dx.doi.org/10.3389/fimmu.2022.904609 |
_version_ | 1784739104691322880 |
---|---|
author | Miller, Nathaniel L. Raman, Rahul Clark, Thomas Sasisekharan, Ram |
author_facet | Miller, Nathaniel L. Raman, Rahul Clark, Thomas Sasisekharan, Ram |
author_sort | Miller, Nathaniel L. |
collection | PubMed |
description | The dynamic interplay between virus and host plays out across many interacting surfaces as virus and host evolve continually in response to one another. In particular, epitope-paratope interactions (EPIs) between viral antigen and host antibodies drive much of this evolutionary race. In this review, we describe a series of recent studies examining aspects of epitope complexity that go beyond two interacting protein surfaces as EPIs are typically understood. To structure our discussion, we present a framework for understanding epitope complexity as a spectrum along a series of axes, focusing primarily on 1) epitope biochemical complexity (e.g., epitopes involving N-glycans) and 2) antigen conformational/dynamic complexity (e.g., epitopes with differential properties depending on antigen state or fold-axis). We highlight additional epitope complexity factors including epitope tertiary/quaternary structure, which contribute to epistatic relationships between epitope residues within- or adjacent-to a given epitope, as well as epitope overlap resulting from polyclonal antibody responses, which is relevant when assessing antigenic pressure against a given epitope. Finally, we discuss how these different forms of epitope complexity can limit EPI analyses and therapeutic antibody development, as well as recent efforts to overcome these limitations. |
format | Online Article Text |
id | pubmed-9247215 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92472152022-07-02 Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies Miller, Nathaniel L. Raman, Rahul Clark, Thomas Sasisekharan, Ram Front Immunol Immunology The dynamic interplay between virus and host plays out across many interacting surfaces as virus and host evolve continually in response to one another. In particular, epitope-paratope interactions (EPIs) between viral antigen and host antibodies drive much of this evolutionary race. In this review, we describe a series of recent studies examining aspects of epitope complexity that go beyond two interacting protein surfaces as EPIs are typically understood. To structure our discussion, we present a framework for understanding epitope complexity as a spectrum along a series of axes, focusing primarily on 1) epitope biochemical complexity (e.g., epitopes involving N-glycans) and 2) antigen conformational/dynamic complexity (e.g., epitopes with differential properties depending on antigen state or fold-axis). We highlight additional epitope complexity factors including epitope tertiary/quaternary structure, which contribute to epistatic relationships between epitope residues within- or adjacent-to a given epitope, as well as epitope overlap resulting from polyclonal antibody responses, which is relevant when assessing antigenic pressure against a given epitope. Finally, we discuss how these different forms of epitope complexity can limit EPI analyses and therapeutic antibody development, as well as recent efforts to overcome these limitations. Frontiers Media S.A. 2022-06-17 /pmc/articles/PMC9247215/ /pubmed/35784339 http://dx.doi.org/10.3389/fimmu.2022.904609 Text en Copyright © 2022 Miller, Raman, Clark and Sasisekharan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Miller, Nathaniel L. Raman, Rahul Clark, Thomas Sasisekharan, Ram Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies |
title | Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies |
title_full | Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies |
title_fullStr | Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies |
title_full_unstemmed | Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies |
title_short | Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies |
title_sort | complexity of viral epitope surfaces as evasive targets for vaccines and therapeutic antibodies |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247215/ https://www.ncbi.nlm.nih.gov/pubmed/35784339 http://dx.doi.org/10.3389/fimmu.2022.904609 |
work_keys_str_mv | AT millernathaniell complexityofviralepitopesurfacesasevasivetargetsforvaccinesandtherapeuticantibodies AT ramanrahul complexityofviralepitopesurfacesasevasivetargetsforvaccinesandtherapeuticantibodies AT clarkthomas complexityofviralepitopesurfacesasevasivetargetsforvaccinesandtherapeuticantibodies AT sasisekharanram complexityofviralepitopesurfacesasevasivetargetsforvaccinesandtherapeuticantibodies |